GDF-15 Biomarker for Predicting COVID-19 Severity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting COVID-19 disease severity and progression, particularly in differentiating between mild and severe cases, which is crucial for resource allocation and patient management during the pandemic.
Innovation Solution
Determining the level of Growth Differentiation Factor-15 (GDF-15) in patient samples and comparing it to a reference to predict disease severity, risk stratification, and monitoring disease progression, as well as predicting the need for intensive care, mortality, thrombosis, and pulmonary embolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for predicting COVID-19 disease severity, then resource allocation and patient management can be performed, but the prediction accuracy and ability to differentiate between mild and severe cases is insufficient
Solution Approach 1:
The patent changes the parameter being measured from general biomarkers to specifically GDF-15 protein levels. By focusing on this single parameter that has been shown to correlate with disease severity, the method achieves both higher prediction accuracy and better reliability in differentiating between mild and severe COVID-19 cases
Solution Approach 2:
GDF-15 serves as an intermediary biomarker that mediates between the virus infection and the severe pathological outcomes. The patent uses GDF-15 as an intermediate indicator to predict disease progression, hospitalization risk, and severe outcomes, providing a reliable bridge for early identification of high-risk patients
2Loss of information
If biomarkers are used to provide prognostic information and predict disease progression, then more targeted therapy stratification can be achieved, but the current biomarkers lack sufficient prognostic value for early risk identification
Solution Approach 1:
The patent enables preliminary identification of patients at high risk for severe outcomes by measuring GDF-15 levels early in the disease course. This preliminary action allows clinicians to prepare and implement targeted interventions before disease progression to severe stages, reducing loss of time in risk identification
Solution Approach 2:
By switching to GDF-15 as the measured parameter, the patent captures prognostic information that is both early in appearance and highly predictive of severe outcomes. The parameter change enables detection of at-risk patients earlier than current biomarkers while providing comprehensive prognostic information
Data Source
AI summary
The present invention relates to a method for predicting the disease severity in a patient with COVID-19, said method comprising a) determining the level of GDF-15 in a sample from the patient with COVID-19, b) comparing the level determined in step a) to a reference, and predicting the disease severity in a patient with COVID-19. Also encompassed are methods for risk stratification, monitoring of the disease progression and the risk prediction for hospital admission in a patient with COVID-19. Furthermore, methods are provided for predicting the need for intensive care, the risk for thrombosis, pulmonary embolism, hypoxia and mortality in a patient with COVID-19.